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Abstract
Introduction: We aimed to compare intensive care unit mortality due to non-pneumococcal severe
community-acquired pneumonia between the periods 2000–2002 and 2008–2014, and the impact of the improvement
in antibiotic strategies on outcomes.
Methods: This was a matched case–control study enrolling 144 patients with non-pneumococcal severe pneumonia:
72 patients from the 2000–2002 database (CAPUCI I group) were paired with 72 from the 2008–2014 period (CAPUCI II
group), matched by the following variables: microorganism, shock at admission, invasive mechanical ventilation,
immunocompromise, chronic obstructive pulmonary disease, and age over 65 years.
Results: The most frequent microorganism was methicillin-susceptible Staphylococcus aureus (22.1 %) followed by
Legionella pneumophila and Haemophilus influenzae (each 20.7 %); prevalence of shock was 59.7 %, while 73.6 % of
patients needed invasive mechanical ventilation. Intensive care unit mortality was significantly lower in the CAPUCI II
group (34.7 % versus 16.7 %; odds ratio (OR) 0.78, 95 % confidence interval (CI) 0.64–0.95; p = 0.02). Appropriate therapy
according to microorganism was 91.5 % in CAPUCI I and 92.7 % in CAPUCI II, while combined therapy and early
antibiotic treatment were significantly higher in CAPUCI II (76.4 versus 90.3 % and 37.5 versus 63.9 %; p < 0.05). In
the multivariate analysis, combined antibiotic therapy (OR 0.23, 95 % CI 0.07–0.74) and early antibiotic treatment
(OR 0.07, 95 % CI 0.02–0.22) were independently associated with decreased intensive care unit mortality.
Conclusions: In non-pneumococcal severe community-acquired pneumonia , early antibiotic administration and use of
combined antibiotic therapy were both associated with increased intensive care unit survival during the study period.
Introduction
In Western countries, community-acquired pneumonia
(CAP) is the leading cause of death and is associated
with high healthcare costs [1]. In the intensive care unit
(ICU) setting, it is one of the most common reasons for
admission and the most frequent causes of mortality [2].
Antibiotic treatment is the cornerstone for management
of pneumonia, and adequate empiric treatment is associ-
ated with improved outcomes [1].
The trend in CAP mortality over recent decades remains
unclear, despite many efforts to identify it. Contrasting re-
sults have been obtained in different publications because
most of them did not differentiate between outpatients, pa-
tients admitted to the ward and patients admitted to the
ICU [3, 4]. Conversely, many recently published studies
have found a significant decrease in mortality in septic
shock [5–7], or in severe respiratory failure requiring inva-
sive mechanical ventilation (IMV) [8]; therefore, it is rea-
sonable to assume that mortality due to severe pneumonia,
especially when complicated with septic shock, may have
decreased in the last few years. In a recent study, we found
a reduction in mortality due to pneumococcal severe
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(S)CAP and an association between better management of
antibiotic therapy and improved ICU survival [9].
The present study hypothesizes that, as in pneumococ-
cal SCAP [9], an improvement in antibiotic policies will
contribute to reducing mortality in non-pneumococcal
SCAP. The primary objective was to determine ICU
mortality due to non-pneumococcal SCAP, and the sec-
ondary objective was to assess whether improvements in
antibiotic prescription had been implemented.
Materials and methods
This was a matched case–control study enrolling 144 ICU
patients diagnosed with non-pneumococcal SCAP: 72 pa-
tients from the CAPUCI I study (2000–2002 period) were
paired with 72 patients from the CAPUCI II database
(2008–2014 period).
CAPUCI I was a multicenter, prospective, observational
study carried out in 33 hospitals in Spain between 2000
and 2002. All patients admitted to ICU with diagnosis of
SCAP were included. CAPUCI II was a follow-up project
endorsed by the European Critical Care Research Net-
work, carried out in 29 European ICUs from 2008 to
2014. In both studies, patients were admitted to the ICU
either to undergo IMV or because they were in an un-
stable clinical condition [1]. All cases were followed until
ICU discharge or death, and all clinical decisions were left
to the discretion of the attending physician. Data from
these cohorts have been reported elsewhere [10]. The Joan
XXIII University Hospital Ethics Board (coordinating
centre) approved the study (REF 2005/NA); the need for
informed consent was waived due to the observational na-
ture of the studies.
Pneumonia was diagnosed when a patient had consistent
clinical findings plus a new pulmonary infiltrate on chest
radiography. Immunocompromise was defined as primary
immunodeficiency or immunodeficiency secondary to ra-
diation treatment, use of cytotoxic drugs or steroids (daily
doses >20 mg prednisolone or equivalent for >2 weeks),
transplantation or AIDS. Shock was defined as the need
for a vasopressor during >4 hours after fluid replacement;
rapid radiographic spread was defined as an increase in the
size of opacities on chest radiograph >50 % at 48 hours.
SCAP was defined as pneumonia that required ICU
admission, with single or multi-organ failure. Patients
proceeding from a long-term care facility, diagnosed
with healthcare-associated pneumonia and with a no-
cardiopulmonary resuscitation indication were not in-
cluded. Microbiological diagnosis required a positive
result from a respiratory sample or blood culture, or a
positive urinary antigen in the case of Legionella spp.
infection. Probability of death was predicted according
to the “estimated risk of mortality” using the Acute
Physiology and Chronic Health Evaluation (APACHE)
II score in the CAPUCI I cohort and Simplified Acute
Physiology Score (SAPS) III in the CAPUCI II cohort
[11, 12]. Monotherapy and combined therapy were de-
fined as administration of the same antibiotic (one or
more) during the first 2 days of ICU admission. Early anti-
biotic administration was defined as administration of the
first dose of antibiotic within 3 hours of hospital admission.
Patients with pneumonia and negative cultures, doc-
umented viral pneumonia or mixed aerobic/anaerobic
flora were excluded; likewise, aspiration pneumonia,
often associated with impaired clinical status [13], was
excluded from the analysis so as to avoid bias. To per-
form the case–control analysis, each patient from the
CAPUCI II group with a confirmed microbial etiology
was matched with one from the CAPUCI I group with
the same microorganism. Subsequently, the rest of vari-
ables used to match patients were: 1) presence of shock
at ICU admission; 2) need for IMV; 3) immunosuppres-
sion; 4) chronic obstructive pulmonary disease; and 5)
age (cut-off, 65 years) [14]; all main determinants for
mortality in CAP [15, 16].
All data management and statistical analyses were per-
formed using the SPSS 20 processor (SPSS inc., Chicago,
IL). Results are expressed as medians and interquartile
range for continuous variables, or as absolute percentages
for categorical variables. Continuous variables were com-
pared with the Mann–Whitney U test (non-normally dis-
tributed variables). Categorical variables were assessed
with the chi-square or two-tailed Fisher exact test.
A multivariate model was performed to identify the vari-
ables associates with changes in mortality. To construct the
model, we performed a logistic regression using all variables
from the univariate analysis that were associated with a dif-
ferent mortality as covariates; subsequently, to optimize the
model and minimize an overfitting bias, an automatic step-
wise backward covariate selection was performed. Thus,
multivariate analysis was finally adjusted according to the
following variables: shock at admission, acute renal failure,
combination therapy and early antibiotic administration.
Kaplan-Meier analysis was used to construct survival
curves for patients receiving combination and monotherapy
regimens and early versus late antibiotic administration.
Results
ICU mortality was significantly lower in the CAPUCI II
group (34.7 versus 16.7 %; odds ratio (OR) 0.78, 95 % con-
fidence interval (CI) 0.64–0.95; p = 0.02). Figure 1 shows a
flow chart analysis for patient selection; in both CAPUCI I
and CAPUCI II populations, mortality among patients en-
rolled in the analysis was compared with mortality of the
rest of patients in the same group, with no significant dif-
ferences being found (Fig. 1). In both cohorts, mortality of
patients enrolled in the case–control analysis did not
present significant differences when compared with pa-
tients not introduced into the analysis. Mortality in the
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CAPUCI I cohort was 34.7 % in patients enrolled in the
analysis versus 33.8 % in non-matched patients with non-
pneumococcal pneumonia with confirmed microorganism
(p = 1.00); in CAPUCI II, it was 16.7 % in matched and
17.4 % in non-matched patients, respectively (p = 1.00).
Figure 2 depicts survival depending on the microbiological
isolate: the most frequent microorganism was Staphylo-
coccus aureus (22.1 %), followed by Legionella pneumo-
phila and Haemophilus influenzae (each 20.7 %). Table 1
shows the variables used to pair patients; individuals
selected for the case–control analysis showed a preva-
lence of shock and IMV of 59.7 % and 73.6 %, respect-
ively. Furthermore, Table 1 shows the prevalence of the
matching variables in patients with non-pneumococcal
bacterial pneumonia not selected for the matching
analysis; no significant differences were observed be-
tween matched and non-matched patients. As indicated
in Table 2, estimated probability of death was 32.0 % in
the CAPUCI II group and 34.0 % in the CAPUCI I
group (p = 0.59). Bacteremia was observed in 22.2 % of
CAPUCI I and in 30.6 % of CAPUCI II (p = 0.35). No
significant differences were observed in length of ICU stay
(10.5 versus 12.0 days; p = 0.16) or length of IMV (8.0 ver-
sus 10.5 days; p = 0.18). Mortality showed an absolute re-
duction of 18 % between the CAPUCI II group (34.7 %)
and the CAPUCI I group (16.7 %) (p = 0.02). Figure 3
compares ICU mortality between groups. In the CAPUCI
II group, it fell significantly in the overall population with
an OR of 0.78 (95 % CI 0.64–0.95; p = 0.02); in venti-
lated patients the OR was 0.70 (95 % CI 0.53–0.91; p = 0.01)
Fig. 1 Flow chart diagram of patient selection and mortality in the different subgroups
Fig. 2 ICU survival according to microorganism
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while in patients with shock it was 0.60 (95 % CI 0.43–0.84;
p < 0.01).
Kaplan-Meier survival analysis was performed in the
whole population and in the subgroups of patients who
underwent IMV or required vasopressors, stratifying by
monotherapy versus combined therapy (Fig. 4; log rank
p value <0.01 in the three analyses) and early versus
non-early antibiotic treatment (Fig. 5; log rank p value <0.01
in all three cases). As shown in Table 3, no significant
ldifferences were observed between bacteremic and
non-bacteremic patients.
Combined therapy was administered in 76.4 % of pa-
tients in the CAPUCI I group and in 90.3 % in the
CAPUCI II group (p = 0.04) (Table 4). Early antibiotic
treatment was also significantly higher in the CAPUCI II
group (63.9 versus 37.5 %; p < 0.01). The most frequent
antibiotic prescription was a cephalosporin plus a
macrolide (Table 5) in 58 out of 144 patients (40.1 %),
with ceftriaxone/cefotaxime plus clarithromycin being
the most frequent combination (29 patients out of 144,
20.1 %). The most frequent pattern delivered in the
CAPUCI I group was ceftriaxone/cefotaxime plus
Table 1 Description of matched variables and mortality
Variable CAPUCI I group CAPUCI I p value CAPUCI II group CAPUCI II p value
(n = 72) non-matched (n = 72) non-matched
Age over 65 years 32 (44.4) 22 (28.6) 0.06 32 (44.4) 23 (41.8) 0.86
COPD 34 (47.2) 24 (31.2) 0.06 34 (47.2) 19 (36.5) 0.27
Immunosuppression 9 (12.5) 17 (22.1) 0.14 9 (12.5) 7 (12.5) 1.00
Shock 43 (59.7) 47 (61.0) 1.00 43 (59.7) 24 (43.6) 0.08
IMV 53 (73.6) 57 (74.0) 1.00 53 (73.6) 32 (60.4) 0.13
ICU mortality 25 (34.7) 26 (33.8) 1.00 12 (16.7) 8 (17.4) 1.00
Data are presented as n (%). COPD chronic obstructive pulmonary disease, ICU intensive care unit, IMV invasive mechanical ventilation
Table 2 Other demographical data and clinical presentations
Variable CAPUCI I group CAPUCI II group p value
(n = 72) (n = 72)
Agea 63.0 (47.5–75.0) 62.0 (53.0–72.0) 0.85
Age under 50 years 20 (27.8) 14 (19.4) 0.33
Age 50–64 years 20 (27.8) 24 (33.3) 0.59
Age 65–74 years 13 (18.1) 20 (27.8) 0.23
Age over 75 years 19 (26.4) 14 (19.4) 0.43
Male gender 49 (68.1) 54 (75.0) 0.46
Active smoker 25 (34.7) 27 (37.5) 0.86
Alcohol use 24 (33.3) 14 (19.4) 0.09
Overweight 14 (19.4) 21 (29.2) 0.24
Diabetes mellitus 18 (25.0) 15 (20.8) 0.69
Cardiomyopathy 24 (33.3) 17 (23.6) 0.27
Cerebral vascular disease 4 (5.6) 7 (9.7) 0.53
Malignancy 6 (8.3) 4 (5.6) 0.75
Estimated probability of deatha 32.0 (19.5–50.0) 34.0 (16.0–62.8) 0.59
ICU length of staya 10.5 (6.0–20.8) 12.0 (7.0–33.0) 0.16
Days of mechanical ventilationa 8.0 (4.0–15.3) 10.5 (6.0–23.3) 0.18
Bacteremia 16 (22.2) 22 (30.6) 0.35
Acute kidney injury 31 (43.1) 29 (40.3) 0.87
Rapid radiographic spread 40 (55.6) 37 (51.4) 0.74
ICU mortality 25 (34.7) 12 (16.7) 0.02
Data are presented as n (%), unless otherwise indicated: a median (interquartile range 25–75). ICU intensive care unit. Significant p values are indicated in bold
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clarithromycin (27 patients out of 72, 37.5 %) while in
the CAPUCI II group it was ceftriaxone/cefotaxime plus
levofloxacin (21 patients out of 72, 17.3 %). Azithromy-
cin was not available in Spain in parenteral formulation
between 2000 and 2002, so it was not used in this group.
Table 6 shows the empiric antibiotic treatment deliv-
ered to each patient, and the appropriateness of the em-
piric antibiotic treatment with respect to the isolated
microorganism. Overall, appropriate therapy based on
bacteriology was 91.5 % in CAPUCI I and 92.7 % in
CAPUCI II. Appropriate therapy was prescribed in all
episodes caused by Staphylococcus aureus, Haemophilus
influenzae, Escherichia coli, Klebsiella pneumoniae,
Mycoplasma pneumoniae and Enterobacter aerogenes.
Inappropriate therapy was only prescribed in episodes
caused by Legionella pneumophila (2/15 and 2/15 in
CAPUCI I and II, respectively) and Pseudomonas aeru-
ginosa (6/11 and 5/11 in CAPUCI I and II, respectively).
Table 7 shows univariate and multivariate analyses for
the assessment of variables associated with different mor-
tality rates. In the univariate analysis, variables associated
with a significant rise in ICU mortality were shock at ICU
admission (p < 0.01), acute kidney injury (p < 0.01), need
for IMV (p = 0.02) and alcohol use (p = 0.03); factors asso-
ciated with lower ICU mortality were combined therapy
(p < 0.01) and early antibiotic treatment (p < 0.01).
Fig. 3 ICU mortality in the whole population and in different subgroups of patients. ICU intensive care unit, IMV invasive mechanical ventilation
Fig. 4 Kaplan-Meier survival curve stratified for monotherapy versus combined therapy. a The whole population (log rank p < 0.01); b patients with
shock (log rank p < 0.01); c patients under mechanical ventilation (log rank p < 0.01). ICU intensive care unit
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As shown in Table 7, we explored whether the adminis-
tration of a specific antibiotic combination was associated
with changes in mortality, without observing significant
differences. We compared mortality after the administra-
tion of either beta-lactam-macrolide (univariate analysis:
OR 0.72, 95 % CI 0.34–1.54) or beta-lactam-quinolone
(univariate analysis: OR 0.43, 95 % CI 0.17–1.14) regi-
mens, without observing significant differences (data not
shown).
Variables from the univariate analysis that were asso-
ciated with significant changes in mortality were intro-
duced in a multivariate model analysis. Acute kidney
injury and shock at ICU admission were associated
with a higher risk of ICU mortality (OR 4.56, 95 % CI
1.60–13.02; and OR 3.96, 95 % CI 1.29–12.14, respectively.
Conversely, early antibiotic treatment (OR 0.07, 95 % CI
0.02–0.22) and combined therapy (OR 0.23, 95 % CI
0.07–0.74) were associated with a lower risk of mortality
during ICU admission.
Furthermore, we explored if the agreement with 2007
Infectious Diseases Society of America/American Thor-
acic Society (IDSA/ATS) guidelines was associated with
an improved outcome, observing a decreased mortality
after delivery of adequate treatment (OR 0.65, 95 % CI
0.48–0.89). When we performed a multivariate analysis
(variable introduced in the model: shock at admission,
acute renal failure and 2007 IDSA/ATS agreement) the as-
sociation was still significantly present (OR 0.39, 95 % CI
0.17–0.91). However, the same association was not present
when, in the same multivariate model, the variables “com-
bination therapy” and “early antibiotic administration”
were added (for mortality for the variable “2007 IDSA/ATS
agreement: OR 0.98; 95 % CI 0.32–2.97).
Discussion
The most relevant conclusions of the present analysis
were the significant decrease in ICU mortality due to
non-pneumococcal SCAP between the two cohorts, and
the positive association between improved empirical
antibiotic treatment and a lower mortality rate. These
findings confirm our primary hypothesis, and are con-
sistent with the results obtained from our previous study
in patients with pneumococcal CAP from the same data-
base [9].
Few published studies have assessed changes in mor-
tality due to CAP in recent years. Moreover, as men-
tioned above, the vast majority did not differentiate
between critical and non-critical patients [3, 4]. How-
ever, several studies have reported a significant decrease
in mortality due to all-source septic shock in recent
Fig. 5 Kaplan-Meier survival curve stratified for early versus non-early antibiotic treatment. a The whole population (log rank p < 0.01); b patients
with shock (log rank p < 0.01); c patients under mechanical ventilation (log rank p < 0.01). ICU intensive care unit
Table 3 Comparison between bacteremic and non-bacteremic
patients
Variable Bacteremic Non-bacteremic p value
(n = 38) (n = 106)
Age under 50 years 9 (23.7) 25 (23.6) 1.00
Age 50–64 years 13 (34.2) 31 (29.2) 0.68
Age 65–74 years 6 (15.8) 27 (25.5) 0.27
Age over 75 years 10 (26.3) 23 (21.7) 0.65
Immunocompromised 7 (18.4) 11 (10.4) 0.25
Shock at ICU admission 23 (60.5) 63 (59.4) 1.00
Invasive mechanical ventilation 28 (73.7) 78 (73.6) 1.00
Acute kidney injury 17 (44.7) 43 (40.6) 0.70
Rapid radiographic spread 24 (63.2) 53 (50.0) 0.19
Combined therapy 34 (89.5) 86 (81.1) 0.31
Antibiotic initiated 0 to 3 hours 18 (47.4) 55 (51.9) 0.71
ICU mortality 11 (28.9) 26 (24.5) 0.67
Data are presented as n (%). ICU intensive care unit
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decades [5–7]. Our results were obtained in a population
with a high rate of IMV (73.6 %) or secondary shock
(59.7 %). In this setting, during the planning of a study,
we believe that is vital to differentiate between critical
and non-critical patients.
To our knowledge, no studies to date have assessed
mortality due to SCAP with regard to etiology. It is worth
noting that, during the matching process, we did not set a
percentage for each microorganism a priori; instead, we
found the number of coincidences between groups ac-
cording to the above-mentioned variables. Interestingly,
the distribution of the identified microorganisms in our
sample coincides with literature reports, thus confirming
the study’s external reproducibility [1, 17].
As indicated in Table 6, the vast majority of patients re-
ceived adequate treatment according to microbiology. As
expected, appropriateness of treatment in case of infection
due to Legionella pneumophila and Pseudomonas aerugi-
nosa was lower. In case of Legionella infection the treat-
ment was adequate in 86.7 % of patients from the CAPUCI
I and II groups. On the other hand, treatment was ad-
equate with respect to microbiology respectively in 45.5
and 54.5 % of patients with infection due to Pseudomonas
aeruginosa. This is important because an inappropriate
treatment can lead to an increased mortality. In fact, the
survival rate in case of Pseudomonas pneumonia was the
lowest when compared with other etiologies (with the ex-
ception of Enterobacter infection; however, this is not sig-
nificant as only four patients were introduced in the
analysis, two in each group), and this is probably due to
the low rate of adequate empirical treatment. Despite this,
an improvement in mortality was observed between the
two periods, and this is probably due to the earlier admin-
istration of the first dose of antibiotic and other general
Table 4 Characteristics of antibiotic treatment
Variable CAPUCI I group CAPUCI II group p value
(n = 72) (n = 72)
Previous antibiotic 14 (19.4) 10 (13.9) 0.50
Monotherapy 17 (23.6) 7 (9.7) 0.04
Combined therapy 55 (76.4) 65 (90.3) 0.04
Antibiotic initiated 0 to 3 hours 25 (37.5) 46 (63.9) <0.01
Antibiotic initiated 4 to 6 hours 21 (29.2) 17 (23.6) 0.57
Antibiotic initiated more than 6 hours 25 (33.3) 9 (12.5) <0.01
Adequate according to 2007 IDSA/ATS guidelines 31 (43.1) 41 (56.9) 0.13
Data are presented as n (%). Significant p values are indicated in bold. IDSA/ATS Infectious Diseases Society of America/American Thoracic Society
Table 5 Most frequent patterns of antibiotic treatment
Variable All patients CAPUCI I group CAPUCI II group p value
(n = 144) (n = 72) (n = 72)
Cephalosporin and macrolide 58 (40.1) 35 (48.5) 23 (32.0) 0.06
Ceftriaxone/cefotaxime and clarithromycin 29 (20.1) 27 (37.5) 2 (2.8) <0.01
Ceftriaxone/cefotaxime and azithromycin 18 (12.4) 0 (0) 18 (25.0) <0.01
Other cephalosporin and macrolide 11 (7.6) 8 (11.1) 3 (4.2) 0.21
Cephalosporin and quinolone 31 (21.5) 6 (8.4) 25 (34.6) <0.01
Cefotaxime/ceftriaxone and levofloxacin 25 (17.3) 4 (5.6) 21 (29.0) <0.01
Other cephalosporin and quinolone 6 (4.2) 2 (2.8) 4 (5.6) 0.68
Penicillin and macrolide 9 (6.3) 2 (2.8) 7 (9.7) 0.17
Piperacillin-tazobactam and azithromycin 5 (3.5) 0 (0) 5 (6.9) 0.06
Other penicillin and macrolide 4 (2.8) 2 (2.8) 2 (2.8) 1.00
Amoxicillin-clavulanate 8 (5.6) 8 (11.1) 0 (0) <0.01
Ceftriaxone/cefotaxime 7 (4.9) 5 (6.9) 2 (2.8) 0.44
Levofloxacin 6 (4.2) 4 (5.6) 2 (2.8) 0.68
Miscellaneous combined therapy 22 (15.3) 12 (16.7) 10 (13.9) 0.78
Miscellaneous monotherapy 3 (2.1) 0 (0) 3 (4.2) 0.25
Overall 144 (100) 72 (100) 72 (100)
Data are presented as n (%). Significant p values are indicated in bold. p value calculated between CAPUCI I and CAPUCI II groups
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Table 6 Treatment of each case of pneumonia and rate of adequate treatment according with the isolated microorganism
Staphylococcus
aureus
Legionella
pneumophila
Haemophilus
influenzae
Pseudomonas
aeruginosa
Escherichia coli Klebsiella
pneumoniae
Mycoplasma
pneumoniae
Enterobacter
aerogenes
C I C II C I C II C I C II C I C II C I C II C I C II C I C II C I C II
Amoxicillin-clavulanate 1 (0) – 1 (1) – 5 (3) – 1 (1) – – – – – – – – –
Cefotaxime/ceftriaxone 3 (1) – 1 (0) 2 (2) – – – – – – – – – – 1 (1) –
Levofloxacin 1 (0) – – – – 1 (0) 1 (1) 1 (1) 2 (1) – – – – – – –
Piperacillin-tazobactam – 1 (0) – – – – – 1 (1) – 1 (0) – – – – – –
Amoxicillin-clavulanate plus macrolide – – 1 (0) 1 (1) – – – – – – – – – – – –
Amoxicillin-clavulanate plus clindamycin – – – – – – – – – 1 (0) – – – – – 1 (0)
Amoxicillin-clavulanate plus levofloxacin – 1 (0) – – – – – – – – – 1 (1) – – – –
Cefotaxime/ceftriaxone plus macrolide 9 (2) 7 (0) 6 (0) 5 (2) 5 (2) 3 (0) 4 (2) 2 (0) 1 (1) 2 (0) 3 (1) – 1 (0) 1 (0) – –
Cefotaxime/ceftriaxone plus aztreonam – – – – – – 1 (0) – – – – – – – – –
Cefotaxime/ceftriaxone plus clindamycin – – – – – – – – – – – – – – – –
Cefotaxime/ceftriaxone plus levofloxacin 1 (1) 2 (0) 1 (1) 5 (0) – 6 (0) – 2 (0) 1 (0) 3 (0) 1 (1) 1 (0) – 1 (0) – 1 (0)
Cefepime/ceftazidime plus macrolide – 1 (0) 1 (0) 1 (0) 3 (0) 1 (0) 1 (1) – 1 (1) – – – – – – –
Cefepime plus amikacin – – – – – – – – 1 (1) – – – – – – –
Cefepime plus ciprofloxacin – – 1 (0) – 1 (0) – – – – – – – – – – –
Cefepime plus levofloxacin – 2 (1) – – – 2 (0) – – – – – – – – – –
Carbapenem/piperacillin-tazobactam plus amikacin – – – – – – 1 (0) – – – – – – – – –
Carbapenem/piperacillin-tazobactam plus
clindamycin
– 1 (0) – – 1 (0) – – – – – – – – – – –
Carbapenem/piperacillin-tazobactam plus
ciprofloxacin
1 (0) – – – – – 2 (1) – – – – – 1 (0) – – –
Carbapenem/piperacillin-tazobactam plus macrolide – 1 (0) 1 (1) – – 1 (1) – 4 (1) – – – – – – 1 (0) –
Levofloxacin plus azithromycin – – – 1 (0) – 1 (0) – – – – – – – – – –
Levofloxacin plus tobramycin – – – – – – – – 1 (0) – – – – – – –
Piperacillin-tazobactam plus levofloxacin – – 2 (0) – – – – 1 (0) – – – 2 (1) – – – –
Overall 16 16 15 15 15 15 11 11 7 7 4 4 2 2 2 2
Adequate according with microorganisma 16
(100)
16
(100)
13
(86.7)
13
(86.7)
15
(100)
15
(100)
5
(45.5)
6
(54.5)
7
(100)
7
(100)
4
(100)
4
(100)
2
(100)
2
(100)
2
(100)
2
(100)
Data are shown as absolute count of patients that received a specific antibiotic regimen; the number of patients who died receiving this antibiotic regimen is shown between parenthesis. a Data are presented as n
(%). C I CAPUCI I, C II CAPUCI II
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improvements that have been made in the last years in the
management of ICU patients.
When exploring mortality depending on the etiology
of pneumonia, we observed an increased survival be-
tween the two cohorts when pneumonia was caused by
Staphylococcus aureus, Haemophilus influenzae, Pseudo-
monas aeruginosa, Escherichia coli and Enterobacter
aerogenes. No changes were observed in case of Klebsi-
ella infection, and an increased mortality was observed
in case of Legionella pneumonia. As shown in Table 3, a
higher proportion of patients from CAPUCI II received
early combination therapy. When exploring the adminis-
tration of mono- versus combination therapy, differenti-
ating by the microorganisms, it becomes evident that all
cases with the exception of Legionella and Pseudomonas
infections received a higher rate of combined therapy if
belonging to the CAPUCI II group (Table 6). Thus, it is
reasonable to assume that the decrease in mortality in
our sample was mainly caused by a higher rate of com-
bination therapy and early antibiotic administration.
In the case of pneumonia due to Legionella pneumo-
phila, an increased mortality between the two groups was
observed. Fifteen patients with Legionella infection were
included in both groups: 3 out of 15 and 5 out 15 died, re-
spectively, in the CAPUCI I and II groups. Among those
who died, two individuals out of three from the CAPUCI I
cohort received microbiological adequate coverture (one
received a quinolone regimen while the other a macrolide
regimen); in CAPUCI II, they were three out of five (all re-
ceived a macrolide regimen) (Table 6). On the other hand,
all patients but one (belonging to the CAPUCI II group)
received delayed antibiotic treatment. We assume that the
small size of the sample, fortuity and probably some
unrecognized factor other than antibiotic therapy played a
role in the different mortality. Due to the low number of
patients that died because of Legionella infection, it is dif-
ficult to ascribe changes in mortality because of the use of
quinolones rather than macrolides, although it is not pos-
sible to exclude it.
In the case of Klebsiella infection, due to the reduced
number of cases (four patients for each group, with 50 %
mortality in both cohorts), it is not possible to take de-
finitive conclusions.
Another important finding is the association between
lower mortality and an improvement in antibiotic strat-
egies; that is, combined antibiotic therapy and early treat-
ment initiation. Combined therapy has become common
practice in the empirical treatment of SCAP [1]. To our
knowledge, no current guideline suggests monotherapy as
empirical therapy. Generally, the recommendation is a
beta-lactam plus either a macrolide or a quinolone. In the
CAPUCI I group, monotherapy was administered in 17
patients (23.6 %) and in 7 patients (9.7 %) in the CAPUCI
II group.
Univariate and multivariate analysis, and Kaplan-Meier
survival analysis, all showed a positive association between
Table 7 Univariate and multivariate analyses to assess variables associated with changes in ICU mortality
Variable Survival No survival Univariate analysis Multivariate analysis:
(n = 107) (n = 37) p value OR (95 % CI); p value
Age over 65 years 46 (43.0) 18 (48.6) 0.57
Overweight 27 (25.2) 8 (21.6) 0.83
Alcohol use 23 (21.5) 15 (40.5) 0.03
Active smoker 36 (33.6) 16 (43.2) 0.33
Diabetes mellitus 24 (22.4) 9 (24.3) 0.83
Cardiomyopathy 28 (26.2) 13 (35.1) 0.30
COPD 49 (45.8) 19 (51.4) 0.57
Immunosuppression 13 (12.1) 5 (13.5) 0.78
Shock at ICU admission 56 (52.3) 30 (81.1) <0.01 3.96 (1.29–12.14); 0.02
Invasive mechanical ventilation 73 (68.2) 33 (89.2) 0.02
Acute kidney injury 36 (33.6) 24 (64.9) <0.01 4.56 (1.60–13.02); <0.01
Rapid radiographic spread 56 (52.3) 21 (56.8) 0.70
Bacteremia 27 (25.2) 11 (29.7) 0.67
Combined therapy 96 (89.7) 24 (64.9) <0.01 0.23 (0.07–0.74); 0.01
AB initiated within 3 hours 67 (62.6) 6 (16.2) <0.01 0.07 (0.02–0.22); <0.01
Combined BL and M therapy 52 (48.6) 15 (40.5) 0.45
Combined BL and FQ therapy 33 (30.8) 6 (16.2) 0.09
Data are presented as n (%). Significant p values are indicated in bold. AB antibiotic, BL beta-lactam, CI confidence interval, COPD chronic obstructive pulmonary
disease, FQ fluoroquinolone, ICU intensive care unit, M macrolide, OR odds ratio
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delivery of combined antibiotic therapy and lower mortal-
ity. Previous studies observed that patients with CAP and
secondary shock or bacteremia [18, 19] presented lower
mortality when combined therapy was delivered. Our re-
sults confirm these findings and, furthermore, suggest that
all patients with severe pneumonia, with or without shock
or need for IMV, may benefit from combined therapy.
Even though this may not be a surprising conclusion, it
should be noted that a significant percentage of our popu-
lation and those in other studies still received monother-
apy [20]. These findings are consistent with those
reported in patients with pneumococcal SCAP [9].
To date, the optimal antibiotic combination choice in
severe CAP is still a debated issue; some authors advo-
cate the use of a macrolide-regimen administration, due
to the anti-inflammatory effects shown by these mole-
cules [21]. However, not all studies achieved similar re-
sults. Although in our cohort the limited size of the
sample makes it difficult to explore this issue, we
assessed changes in mortality after macrolide or quin-
olone administration, in the whole population (Table 7)
and in the subgroups of patients with shock or under
mechanical ventilation (data not shown)—no differences
were observed. Furthermore, several studies concluded
that quinolone administration is comparable in terms of
mortality with a macrolide regimen, but with a higher
eradication rate, a lower treatment failure and possibly
less cost of treatment [22]; however, concerns about an
increased resistance rate after quinolone administration
were raised [23]. Moreover, in case of a social environ-
ment with high rates of pulmonary tuberculosis, the use
of a fluoroquinolone could mask a pulmonary tubercu-
losis rather than bacterial CAP [24]. In our sample, the
use of a quinolone regimen showed a trend to lower
mortality, without achieving significant results, in the
whole population and in the subgroups of patients with
shock or under mechanical ventilation. According to
the present results, it is not possible to advocate the use
of a specific antibiotic family.
In 2006, Kumar et al. showed that mortality rates in
septic patients with shock increased in line with the
delay in antibiotic initiation [25]. Subsequent other stud-
ies of patients with shock confirmed this finding [26]. As
shown in the Kaplan-Meier survival analysis (Fig. 5),
early antibiotic treatment in our sample was associated
with lower mortality not only in the subgroup of patients
with shock, but in the overall population and in the sub-
group of ventilated patients as well. In view of these
findings, each patient who presents at the emergency
room with non-pneumococcal SCAP should receive the
first dose of antibiotic treatment within the first 3 hours.
Indeed, the 2007 IDSA/ATS guidelines recommend initi-
ation of antibiotic therapy before transfer to the ward or
to the ICU [1].
We explored if the agreement with the 2007 IDSA/ATS
guidelines was associated with different outcomes, and we
found a reduced mortality when guideline recommenda-
tions were followed. Basically, IDSA/ATS guidelines rec-
ommend the administration of an early combination of
specific antibiotic families; thus, to better investigate the
effects of simple medical actions on mortality, we decided
to separate the item “2007 IDSA/ATS adequate treatment”
into two variables: “combined therapy” and “early anti-
biotic treatment”. Thus, after the addition of these two
variables in the multivariate model this association was no
longer documented. This might suggest that the sum of
actions that imply the agreement to international guide-
lines is better investigated by separating these actions in
multiple variables rather that grouping all actions into the
variable “2007 IDSA/ATS adequate treatment”.
The current study has some limitations that should be
mentioned. The most important is its observational na-
ture; however, this approach is the only way to assess
changes in outcome over a period of time. Moreover, in
the ICU setting in recent decades there have been sig-
nificant improvements in the management of patients
undergoing IMV or resuscitation of septic shock, and in
nutrition, in the prevention of ICU-related complica-
tions and in the ICU admission criteria as well. Severity-
of-illness was recorded with different scores; in CAPUCI
I the risk of mortality was estimated using APACHE II
score while in CAPUCI II SAPS III was used. However,
both scales reflect a reliable risk of death and were
widely validated in large-scale studies. For this, after esti-
mating the risk of death with APACHE II and SAPS III
scores, we created a variable named “estimated probabil-
ity of death”, comparing both groups. Furthermore, to
avoid an overlap between the same parameters in differ-
ent variables, we decided not to use severity-score vari-
ables to match patients; in fact, both APACHE II and
SAPS III scores include parameters of severity for re-
spiratory or cardiac failure, and demographics such as
age, which were introduced independently in the match-
ing. Of note, the ICUs that participated in CAPUCI I
and II studies were different; in fact, CAPUCI I was de-
veloped in 33 Spanish ICUs while CAPUCI II was car-
ried out in 29 ICUs–24 from Spain and 5 from other
European countries. This may originate a bias due to a
different source of patients; however, after the matching
process, we retrospectively observed that all 72 patients
from the CAPUCI II cohort were enrolled from Spanish
ICUs, thus minimizing the risk of a significant bias. More-
over, we did not perform genetic investigations, although
recent publications have identified common variants in
specific genes that are associated with different outcomes
in severe pneumonia [27]. Finally, as stated by Waterer
[28], ICU outcome often differs from hospital outcome or
from outcome on day 60 or 90 after admission. However,
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as shown in the Kaplan-Meier survival analysis, the major-
ity of deaths in our sample occurred within 14 days of ad-
mission. Although it is true that ICU mortality may differ
from hospital or 3-month outcome, we feel that deferring
excessively the time of the study of the outcome may com-
plicate the analysis, because more variables that are diffi-
cult to record and interpret have to be introduced in the
analysis as confounding variables.
Conclusions
In the current study, mortality due to non-pneumococcal
SCAP decreased between the two cohorts, and the use of
combined antibiotic therapy and early antibiotic adminis-
tration were associated with lower mortality. These finding
agree with the conclusions obtained in a previous study
carried out in patients with pneumococcal SCAP from the
same database [9]. More studies to confirm these findings
are now needed. In the meantime, all patients presenting
at the emergency department with SCAP should receive
two antibiotics within 3 hours of admission.
Key messages
 In the last 14 years, a significant reduction in ICU
mortality due to severe community-acquired pneu-
monia was observed.
 In severe non-pneumococcal community-acquired
pneumonia, early antibiotic administration and com-
bination therapy were associated with a significant
improved survival.
 A lower mortality was observed following early
administration of combination therapy either in the
subgroups of patients with shock, under mechanical
ventilation and without shock or requirement of
mechanical ventilation.
 The most frequent etiologies in severe CAP in the
present cohort were Staphylococcus aureus followed
by Legionella pneumophila and Haemophilus
influenzae.
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